Serum/plasma micro-RNA marker for detecting patients with mild cognitive impairment and application thereof

A technology of mild cognitive impairment and markers, applied in the application of serum/plasma microRNA, detecting the field of serum/plasma microRNA markers in patients with mild cognitive impairment, can solve the diagnostic sensitivity and Limited specificity and other issues, to achieve the effect of high sensitivity and simple operation
CN104480106AInactive Publication Date: 2015-04-01THE FIRST HOSPITAL OF HEBEI MEDICAL UNIV
0 Cites 9 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
THE FIRST HOSPITAL OF HEBEI MEDICAL UNIV
Publication Date
2015-04-01
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the field of biotechnology and neurocognitive and relates to a serum / plasma micro-RNA marker for detecting patients with mild cognitive impairment and an application thereof. The maker is any one or a combination of miR-206 and miRNA-132. The marker is applied in diagnosis of patients with mild cognitive impairment, and the marker is applied in preparation of a kit for diagnosis of patients with mild cognitive impairment. According to the application of the marker, content of serum / plasma miR-206 and / or miRNA-132 of a testee is detected by a real-time fluorescence quantitative polymerase chain reaction (Real-time PCR) method, and the content of the testee is compared with that of a normal cognitive subject to diagnose mild cognitive impairment. The screened miRNA marker has cognitive impairment specificity, is simple to operate diagnosis of mild cognitive impairment, has high sensitivity and is suitable for large-scale screening.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the application of serum / plasma microRNA (miRNA, referred to as miRNA), in particular to the detection of serum / plasma microRNA markers in patients with mild cognitive impairment and the application thereof, belonging to the technical fields of biotechnology and neurocognitive technology. Background technique

[0002] Alzheimer's disease (AD) is a neurodegenerative disease that seriously threatens human health. Mild cognitive impairment (MCI) is a transitional state between Alzheimer's disease and normal aging. Studies have shown that 23% of patients with mild cognitive impairment will progress to Alzheimer's disease within 2 years, and 50% of patients will develop Alzheimer's disease within 4 years. Therefore, mild cognitive impairment is considered to be the most appropriate early intervention treatment for Alzheimer's disease stage. With the aging of the global population, the prevalence of mild cognitive impairment has in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More